EVOKE PHARMA INC's ticker is EVOK and the CUSIP is 30049G104. A total of 21 filers reported holding EVOKE PHARMA INC in Q2 2017. The put-call ratio across all filers is - and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2021 | $1,000 | 0.0% | 490 | 0.0% | 0.00% | – |
| Q4 2020 | $1,000 | -99.8% | 490 | -99.8% | 0.00% | – |
| Q1 2018 | $416,000 | -8.0% | 200,000 | 0.0% | 0.00% | – |
| Q4 2017 | $452,000 | – | 200,000 | +99900.0% | 0.00% | – |
| Q2 2017 | $0 | -100.0% | 200 | -86.7% | 0.00% | – |
| Q1 2017 | $4,000 | -20.0% | 1,500 | +41.2% | 0.00% | – |
| Q2 2015 | $5,000 | +150.0% | 1,062 | +164.2% | 0.00% | – |
| Q4 2014 | $2,000 | – | 402 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Opaleye Management Inc. | 242,500 | $1,962,000 | 1.69% |
| SOPHROSYNE CAPITAL LLC | 49,000 | $397,000 | 0.40% |
| LMR Partners LLP | 23,882 | $187,000 | 0.02% |
| GEODE CAPITAL MANAGEMENT, LLC | 10,276 | $80,000 | 0.00% |
| BlackRock Investment Management, LLC | 489 | $4,000 | 0.00% |
| MORGAN STANLEY | 500 | $4,000 | 0.00% |
| Tower Research Capital LLC (TRC) | 84 | $1,000 | 0.00% |
| VANGUARD GROUP INC | 48,394 | $378,000 | 0.00% |
| UBS AG | 727 | $6,000 | 0.00% |
| BANK OF AMERICA CORP /DE/ | 33,500 | $271,000 | 0.00% |